SCHEMBL1863191

SCHEMBL1863191

CCCCCCCCn1ccc(N)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.46
TLR8 Q9NR97 3/20 0.43
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
HTT P42858 4/20 0.41
GALR3 O60755 2/20 0.41
POLB P06746 2/20 0.41
ATM Q13315 2/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HSP90AA1 P07900 1/20 0.41
MAPT P10636 1/20 0.41
RAD52 P43351 1/20 0.41
PAX8 Q06710 1/20 0.41
NR2F2 P24468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1862049 1.00 KDR (0.46) KDRTLR8ALDH1A1TDP1NPC1
SCHEMBL9729198 1.00 KDR (0.46) KDRTLR8ALDH1A1TDP1NPC1
SCHEMBL474839 0.98 TLR8 (0.44) KDRTLR8ALDH1A1TDP1NPC1
SCHEMBL1860836 0.92 ALDH1A1 (0.44) KDRTLR8ALDH1A1TDP1POLB
SCHEMBL1859454 0.84
SCHEMBL6302339 0.80 ALDH1A1 (0.38) KDRTLR8ALDH1A1TDP1MEN1
SCHEMBL9020965 0.79 NPC1 (0.42) KDRALDH1A1NPC1RAB9AHTT
SCHEMBL1857052 0.79 ALDH1A1 (0.41) ALDH1A1TDP1NPC1RAB9AHTT
SCHEMBL9020584 0.79 NPC1 (0.42) KDRALDH1A1NPC1RAB9AHTT
SCHEMBL17943853 0.79 NPC1 (0.42) KDRALDH1A1NPC1RAB9AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 KDR 3896/4885TLR8 4576/4885ALDH1A1 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.